Pfizer said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai ...

The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity ...

Pfizer said on Tuesday it had entered into an exclusive licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun ...

An artificial intelligence-based endoscopic scoring system may better reflect symptoms and quality of life in ulcerative ...

College students may plan an appointment during winter break and inquire about GLP-1 medications. What should a primary care ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, ...

Pfizer Inc. has entered into an exclusive global collaboration and licensing deal with a unit of Shanghai Fosun ...

Pfizer announced it has entered into an exclusive global collaboration and license agreement with Chongqing Yao ...

Pfizer is rolling the dice again on an oral obesity pill. The pharmaceutical giant signed an exclusive global license agreement with YaoPharma, a subsidiary of China’s Fosun Pharma. The deal involves ...

Pfizer and Moderna’s Covid-19 franchises were already under pressure as the pandemic faded and most people have opted to skip yearly shots. Read more at straitstimes.com. Read more at straitstimes.com ...

Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by ...